Bank of America Securities analyst Lisa Lewandowski reiterated a Sell rating on Cronos Group (CRON – Research Report) yesterday and set a price target of $1.55. The company’s shares closed yesterday at $1.75.
According to TipRanks, Lewandowski is ranked #1055 out of 8491 analysts.
Cronos Group has an analyst consensus of Hold, with a price target consensus of $2.46.
See the top stocks recommended by analysts >>
Based on Cronos Group’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $20.14 million and a GAAP net loss of $19.17 million. In comparison, last year the company earned a revenue of $25.03 million and had a GAAP net loss of $32.64 million
Based on the recent corporate insider activity of 114 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRON in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cronos Group, Inc. engages in the production and sale of cannabis in federally legal jurisdictions, including Canada and Germany. Its portfolio includes Peace Naturals, Original BC (OGBC) and Whistler Medical Marijuana Company (WMMC). The company was founded by Lorne Michael Gertner and Paul Rosen on August 21, 2012 and is headquartered in Toronto, Canada.
Read More on CRON:
- Cronos Group Reports 2023 Second Quarter Results
- Here’s What You Missed in Cannabis This Week
- Rising High: Exclusive talk with biotech company Tryp Therapeutics
- Rising High: Exclusive talk with biotech company Enveric Biosciences
- Cronos Group Inc. to Hold 2023 Second Quarter Earnings Conference Call on August 8, 2023
